Recombinant Proteins Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The report covers Global Recombinant Protein Manufacturers & Companies. The market is Segmented by Product (Hormone, Growth Factor, Antibody, Enzyme, and Other Products), Application (Research Application, Therapeutic Use, and Biotechnology Industry), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market size and forecasts are provided in terms of value (USD million) for all the above segments.

Recombinant Proteins Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Recombinant Proteins Market Size

Recombinant Protein Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 2.90 Billion
Market Size (2030) USD 4.25 Billion
CAGR (2025 - 2030) 7.91 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Recombinant Protein Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Recombinant Protein Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Recombinant Proteins Market Analysis

The Recombinant Protein Market size is estimated at USD 2.90 billion in 2025, and is expected to reach USD 4.25 billion by 2030, at a CAGR of 7.91% during the forecast period (2025-2030).

The COVID-19 pandemic impacted the growth of the recombinant protein market. With the emergence of COVID-19, there has been an increased demand for therapeutic and vaccination measures to combat it. Many market players and public organizations shifted their focus to research and development activities for the treatment of COVID-19, and recombinant proteins played a vital role in these activities, impacting the COVID-19 recombinant protein vaccine market and the recombinant therapeutic antibodies proteins market. For instance, an article published in the journal JCLA in May 2022 reported that researchers and scientists targeted recombinant proteins for COVID-19 vaccine development. Thus, COVID-19 sparked a surge in demand for recombinant protein-based medicines, significantly influencing the global recombinant protein market. However, in the current scenario, it is anticipated that, with the high prevalence of other chronic diseases and the presence of other infectious diseases, and the efficacy of recombinant protein-based medicine in its treatment, the studied market is expected to witness significant growth over the forecast period.

The factors that are driving the growth of the studied market are the increasing expenditure on research and development; the growing prevalence of chronic diseases; the aging population; the rising inclination towards biologics and biosimilars; and the launch of advanced recombinant products, such as those offered by leading recombinant protein manufacturers and recombinant protein companies.

According to the American Cancer Society's 2022 statistics, in the United States, there will be an estimated 1,918,030 new cancer cases in 2022. Such a high burden of cancer creates the need for advanced therapeutics for the treatment, and since recombinant proteins are largely used in therapeutics and the development of cancer therapies, an increase in the cancer burden is expected to drive the demand for recombinant proteins in the protein-based therapeutics market, thereby driving the market's growth.

Additionally, increasing investments in research and development aimed at the introduction of new recombinant protein therapeutics also contribute to the growth of the market. For instance, in May 2022, an update from the National Institutes of Health (NIH) of the United States reported that about USD 1,021 million had been invested in the year 2021 for the research and development funding for autoimmune diseases in the NIH of the United States, and it is further expected to increase to USD 1,061 million in 2022. Thus, such an increase in investment is leading to the development of recombinant-based protein medicines, boosting the protein production market and thus fueling the growth of the studied market.

Furthermore, in September 2021, Aviva Systems Biology, one of the recombinant protein manufacturers engaged in manufacturing and developing antibodies, immunoassay kits, and recombinant proteins for life science research, launched its new protein-on-demand, semi-custom recombinant protein portfolio, contributing to the growth of the custom protein services market for life scientists conducting basic research and preclinical studies.

Thus, due to the increasing expenditure on research and development, the growing prevalence of chronic diseases, the aging population, the rising inclination towards biologics and biosimilars, and the launch of advanced recombinant products, the recombinant protein market size is expected to project significant growth over the forecast period. However, the time-consuming and high-cost of protein manufacturing and production processes may hamper the market's growth over the forecast period.

Recombinant Proteins Industry Overview

The recombinant protein market is moderately competitive due to the presence of several recombinant protein manufacturers operating globally and regionally. The competitive landscape includes an analysis of a few international as well as local recombinant protein companies that hold market shares and are well known, such as AbbVie Inc., Amgen Inc., Bio-Rad Laboratories Inc., Eli Lilly and Company, Merck KGaA, Novo Nordisk A/S, Sanofi S.A., Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline PLC, Novavax Inc., GigaGen Inc., and Pfizer Inc.

Recombinant Proteins Market Leaders

  1. Eli Lilly and Company

  2. Thermo Fisher Scientific Inc.

  3. Novartis AG

  4. GlaxoSmithKline PLC

  5. Pfizer Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Recombinant Protein Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Recombinant Proteins Market News

  • September 2022: the life science group Sartorius, through its French-listed subgroup Sartorius StedimBiotech, acquired AlbumedixLtd. Albumedix is one of the key players in the field of recombinant albumin-based solutions and is based in Nottingham, UK.
  • September 2022: Attralus, Inc., released preclinical data for AT-02, the company's lead pan-amyloid removal (PAR) therapeutic candidate. The AT-02 pan-amyloid elimination studies suggest that this chemical has the potential to provide therapeutic advances. In a systemic amyloidosis progressive animal model, the decrease of cardiac amyloid deposits by 50% is remarkable.

Recombinant Proteins Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Expenditure on Research and Development
    • 4.2.2 Growing Burden of Chronic Diseases
    • 4.2.3 Rising Inclination toward Biologics and Biosimilars
    • 4.2.4 Technological Advancements in Recombinant Products
  • 4.3 Market Restraints
    • 4.3.1 Expensive and Time-consuming Production Process
  • 4.4 Porters' Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Hormone
    • 5.1.2 Growth Factor
    • 5.1.3 Antibody
    • 5.1.4 Enzyme
    • 5.1.5 Other Types of Products
  • 5.2 By Application
    • 5.2.1 Research Application
    • 5.2.2 Therapeutic Use
    • 5.2.3 Biotechnology Industry
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 Bio-Rad Laboratories Inc.
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 Merck KGaA
    • 6.1.6 Novo Nordisk AS
    • 6.1.7 Sanofi SA
    • 6.1.8 Thermo Fisher Scientific Inc.
    • 6.1.9 Novartis AG
    • 6.1.10 GlaxoSmithKline PLC
    • 6.1.11 Novavax Inc.
    • 6.1.12 Pfizer Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Recombinant Proteins Industry Segmentation

As per the scope of the report, recombinant proteins are encoded by recombinant DNA, which involves the insertion of the DNA encoding that particular protein into bacterial or mammalian cells. The protein is then purified after being expressed in these cells. Recombinant proteins are produced either by molecular cloning or by polymerase chain reaction (PCR).

The recombinant protein market is segmented by product (hormones, growth factors, antibodies, enzymes, and other products), application (therapeutic use, research applications, and biotechnology industry), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product Hormone
Growth Factor
Antibody
Enzyme
Other Types of Products
By Application Research Application
Therapeutic Use
Biotechnology Industry
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Recombinant Proteins Market Research FAQs

How big is the Recombinant Protein Market?

The Recombinant Protein Market size is expected to reach USD 2.90 billion in 2025 and grow at a CAGR of 7.91% to reach USD 4.25 billion by 2030.

What is the current Recombinant Protein Market size?

In 2025, the Recombinant Protein Market size is expected to reach USD 2.90 billion.

Who are the key players in Recombinant Protein Market?

Eli Lilly and Company, Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline PLC and Pfizer Inc. are the major companies operating in the Recombinant Protein Market.

Which is the fastest growing region in Recombinant Protein Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Recombinant Protein Market?

In 2025, the North America accounts for the largest market share in Recombinant Protein Market.

What years does this Recombinant Protein Market cover, and what was the market size in 2024?

In 2024, the Recombinant Protein Market size was estimated at USD 2.67 billion. The report covers the Recombinant Protein Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Recombinant Protein Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Recombinant Protein Industry Report

The global recombinant protein market is segmented by product, application, and geography, providing a comprehensive industry analysis. The market report highlights the growth rate, industry outlook, and market trends that are driving the market growth. The market segmentation includes products such as hormones, growth factors, antibodies, enzymes, and other products. The application segments cover research applications, therapeutic use, and the biotechnology industry.

The industry reports provide detailed market data, including market value and market share, offering insights into market leaders and market predictions. The market analysis also includes a market forecast, which outlines the expected market growth over the coming years. The industry research and industry statistics presented in the report give a thorough market overview, helping stakeholders understand the market size and market outlook.

Additionally, the report includes a market review of the geographic regions, namely North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The industry information provided in the report example and report PDF is essential for research companies and those interested in market segmentation and market value. This comprehensive industry overview offers a clear picture of the market trends and market data, ensuring that industry sales and market growth are well understood.